Bain Capital, Mitsubishi tanabe pharma

Bain Capital to Buy Mitsubishi Chemical’s Pharma Business for More Than $3 Billion
The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a bid to focus on its key businesses.
Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion
U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry.
Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation
Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") in a carve-out transaction from Mitsubishi Chemical Group Corporation.
Bain Is Said to Near $3 Billion Deal for Mitsubishi Pharma Unit
Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter said, adding to a dealmaking boom in Japan.
Mitsubishi Chemical to sell drug unit to Bain in $3.36 billion deal
Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it seeks to streamline its portfolio.
Mitsubishi Chemical to sell pharma unit to Bain Capital for $3.36 billion
Mitsubishi Chemical, a Japanese corporation has agreed to sell its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, to U.S. private equity firm Bain Capital, according to Reuters on Friday.
Bain Capital Nears Acquisition of Mitsubishi’s Pharma Division in $3.2 Billion Deal
Dubai Bain Capital is in the final stages of negotiations to acquire Mitsubishi Chemical Group’s pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, for over 500 billion yen . This move aligns with Mitsubishi Chemical’s strategy to streamline its operations and concentrate on core sectors such as vehicle electrification,
M&A News: Bain Capital Buys 350-Year-Old Japanese Drugs Firm for $3.4 billion
Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...
Bain buys 340-year-old pharma company to fast-track Japan’s drug development
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine ...
Plastics News18h
Hillenbrand sells majority stake in Milacron machinery business to Bain Capital for $287M
Hillenbrand Inc. has announced the sale of a 51 percent stake in its Milacron injection molding and extrusion machinery ...
Becker's ASC16h
Why Bain Capital's $3.2B bid for Surgery Partners could 'glaringly outline' PE's impact
Brentwood, Tenn.-based Surgery Partners received a nonbinding acquisition proposal from Bain Capital Private Equity on Jan. 27, offering to buy all outstanding shares for $25.75 per share in cash.
Pensions&Investments19h
Bain Capital chooses capital markets head for real estate division
Keith Largay joined Bain Capital’s real estate business as head of real estate capital markets, a spokesperson confirmed. It ...
Canadian Plastics1d
Bain Capital buys majority stake in Milacron
An affiliate of Bain Capital will acquire 51 per cent of the injection molding and extrusion machinery maker from current owner Hillenbrand Inc.
Bain Capital Announces Majority Investment in Milacron, a Leading Global Provider of Highly Engineered Plastic Processing Solutions
Bain Capital, a leading private investment firm, today announced a majority investment in the Milacron Injection Molding and Extrusion business (or the "Company"), a globally renowned provider of ...
Plastics News1d
Hillenbrand sells majority stake in Milacron to Bain Capital for $287M
Hillenbrand Inc. has announced the sale of a 51% stake in its Milacron injection molding and extrusion business to an ...
Bain Capital Specialty Finance issues $350M in senior notes
Bain Capital Specialty Finance , Inc. (NYSE:BCSF), a specialty finance company with a market capitalization of $1.17 billion and trading near its 52-week high of $18.35, announced the issuance of $350 ...